* SILEXION, A CLINICAL-STAGE, ONCOLOGY-FOCUSED BIOTECHNOLOGY COMPANY, TO BECOME PUBLICLY TRADED VIA BUSINESS COMBINATION WITH MORINGA ACQUISITION CORP
* MORINGA ACQUISITION CORP - BUSINESS COMBINATION PROVIDES FOR SILEXION'S PRE-TRANSACTION EQUITY VALUE TO BE $62.5 MILLION
* MORINGA ACQUISITION CORP - BUSINESS COMBINATION UNANIMOUSLY APPROVED BY BOARDS OF DIRECTORS OF SILEXION AND MORINGA
* MORINGA ACQUISITION CORP - BOARD OF DIRECTORS OF COMBINED COMPANY WILL CONSIST OF SEVEN MEMBERS, OF WHOM TWO WILL BE APPOINTED BY MORINGA'S SPONSOR
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.